UK Medical Cannabis Prescriptions Surge 262%: 80,000 Patients and a GBP 500M Private Market

What happens when 99% of a country’s medical cannabis prescriptions come from private clinics — and the NHS has issued fewer than five?

Seven years after the UK legalised cannabis-based products for medicinal use (CBPMs), the numbers are no longer incremental. Between 2022 and 2024, the total volume of medical cannabis flower prescribed to UK patients surged by 262% â�� from approximately 2,700 kg to nearly 10,000 kg. Prescription counts more than doubled in a single year, climbing from around 283,000 in 2023 to 659,000 in 2024. And by the end of 2025, an estimated 80,000 patients were receiving treatment through the UK’s private medical cannabis system.

These are not projections from a speculative white paper. They are drawn from Home Office import records, NHSBSA Freedom of Information data, and clinical registry figures that collectively paint the picture of a market entering a new phase. The UK’s medical cannabis market was valued at approximately $298 million (GBP ~240 million) in 2025, with Prohibition Partners estimating it surpassed EUR 269 million in sales â�� making it Europe’s second-largest medical cannabis patient market behind Germany. Projections indicate that figure will reach EUR 619 million (GBP ~539 million) by 2029, with patient numbers approaching 190,000.

What makes this growth remarkable is not simply its scale, but its structure. More than 99% of all medical cannabis prescriptions in the UK come through private clinics. The NHS has issued fewer than five cannabis prescriptions to date. This is a market built almost entirely on private healthcare infrastructure â�� and understanding how that infrastructure works, who controls the supply chain, and where the regulatory bottlenecks remain is essential for operators, investors, and healthcare professionals watching Europe’s fastest-growing medical cannabis economy.

The 262% Prescription Surge: What the Data Actually Shows

The headline figure � a 262% rise in prescription volumes since 2022 � comes from matched dispensing data tracked by industry analysts cross-referencing Home Office import records with pharmacy-level prescription information. This is not a single data point but a trend confirmed across multiple indicators.

Year-over-Year Growth

The growth rate between 2022 and 2023 was 94%, followed by 87% between 2023 and 2024. When measured by the number of cannabis medications dispensed rather than prescription events, the 2024-to-2025 increase was even steeper at 130%.

Import Volumes Tell the Supply-Side Story

The UK imported approximately 15.5 tonnes of medical cannabis in 2024 � roughly double the 7-8 tonnes imported in 2022-2023. By August 2025, official data already reflected over 12 tonnes of imports, indicating the full-year figure would significantly exceed 2024. Early 2025 data showed January and February alone exceeding one tonne of matched flower volume, a figure that took months to reach in prior years.

The Shift Toward Higher Potency

A notable trend within the data is the shift toward higher-potency cannabis products. In 2022, roughly 57% of matched volume was between 18-22% THC, with only 11% stronger than 22% THC. By the first two months of 2025, products above 22% THC made up almost half of all matched volume � a sign of maturing patient preferences and growing clinician confidence in higher-dose regimens.

The Private Clinic Engine: Who Is Prescribing and Who Is Supplying

The UK medical cannabis market is, in practical terms, a private healthcare market. Understanding its growth requires understanding the clinics, prescribers, and importers that form its infrastructure.

The Clinic Landscape

As of early 2026, the UK has approximately 40+ private clinics providing medical cannabis treatment, with around 20-25 specialist cannabis clinics actively prescribing. These range from established multi-site operations to telehealth-focused platforms conducting consultations via video call and delivering products by post.

The major players include:

• Curaleaf Clinic (formerly Sapphire Medical Clinics) â�� The highest-rated medical cannabis clinic in the UK, named Cannabis Clinic of the Year 2024. Sapphire was acquired by Curaleaf International, Europe’s largest vertically integrated medical cannabis company, creating a prescriber-to-supplier pipeline.
• Mamedica â�� Part of the Lyphe Group, one of the UK’s most established medical cannabis organisations.
• Releaf â�� A digital-first clinic offering online consultations and home delivery, with a large patient survey programme contributing real-world evidence.
• Zerenia Clinics â�� Operates both in the UK and internationally, offering specialist cannabis consultations.
• The Medical Cannabis Clinics (TMCC) â�� One of the early private prescribers, focused on conditions including chronic pain, anxiety, and PTSD.
• Alternaleaf, Elios Clinics, Cannabis Access Clinics, and others â�� A growing tier of clinics expanding patient access through competitive pricing and streamlined onboarding.

Prescriber Concentration

A striking feature of the market is its prescriber concentration. FOI data obtained from NHSBSA reveals that just 10 doctors prescribed over half (52%) of all medical cannabis treatments issued between 2019 and early 2025 � more than 805,000 cannabis treatments combined. A single consultant was responsible for 10% of all cannabis medicines prescribed, dispensing approximately 46,000 items in the first five months of 2025 alone � equivalent to one prescription every two working minutes.

This concentration reflects a broader problem: of approximately 100,000 doctors on the GMC Specialist Register who are legally permitted to initiate CBPM prescriptions, only around 180 clinicians are actively doing so � fewer than 1%. Lack of training, institutional caution, and absence of updated clinical guidelines are the primary barriers.

Supply Chain Dominance

At the import level, the market is even more concentrated. Curaleaf Laboratories handled more than half (~54%) of all matched flower volume in 2024, with IPS Pharma taking a further ~19.5%. Together, these two companies control over 70% of the matched supply.

IPS Pharma recently signed a landmark GBP 7 million+ import agreement with New Zealand producer Puro � the largest certified organic cannabis supply deal of its kind globally � signalling continued investment in diversifying the supply base.

Where Does the Cannabis Come From? The UK’s Import Map

The UK does not currently permit large-scale domestic cultivation of medical cannabis, which means the entire prescribed supply is imported. Home Office import data reveals the geographic spread of the UK’s cannabis supply chain in 2024.

Top Supplier Countries by Volume (2024)

Spain leads in volume, though a significant proportion of Spanish and Canadian imports are products that have been grown in third countries, imported, processed, and re-exported to the UK. Portugal’s role is particularly notable â�� the country accounted for around 58% of flower volume imported through certain channels in 2024, and its total medical cannabis exports grew 54% year-on-year in 2024, reaching over 18 tonnes globally. Of Portuguese exports, the UK receives approximately 10%, following Germany (46%), Spain (20%), and Poland (16%).

The NHS Access Gap: Why 99% of Patients Go Private

Perhaps the most significant structural feature of the UK medical cannabis market is the near-total absence of NHS prescribing. Despite CBPMs being reclassified to Schedule 2 in November 2018, the NHS has issued fewer than five cannabis prescriptions in seven years. This is not a statistical rounding error � it reflects deep institutional and regulatory barriers.

Why the NHS Is Not Prescribing

NICE guidelines are restrictive. The National Institute for Health and Care Excellence currently recommends CBPMs for only a narrow set of conditions â�� primarily treatment-resistant epilepsy (Epidyolex) and spasticity in multiple sclerosis (Sativex/nabiximols). NICE’s position is that the evidence base for broader indications remains insufficient, despite extensive real-world data from private registries showing 97% of patients reporting improved quality of life.

GPs cannot initiate prescriptions. Under current rules, only doctors on the GMC Specialist Register can prescribe unlicensed CBPMs. General practitioners are excluded from initiating treatment, though they may continue a prescription started by a specialist. Electronic prescribing for CBPMs is still unavailable within the NHS system.

Institutional inertia and stigma. Many NHS trusts have no internal policy on CBPMs, and individual consultants face career risk in prescribing a product class that remains culturally stigmatised within mainstream medicine. Training programmes on cannabinoid medicine are sparse and not integrated into standard medical education.

Cost and procurement barriers. Without NICE approval for broader indications, NHS Clinical Commissioning Groups have no incentive or mechanism to fund CBPM prescriptions. Private patients typically spend GBP 150-500 per month on medication and consultations � costs the NHS is not structured to absorb without formal approval pathways.

The ACMD Review: A Potential Turning Point

In June 2025, the Home Office commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct its most comprehensive review of the UK’s CBPM framework since legalisation in 2018. The call for evidence ran from 17 September to 17 October 2025, inviting submissions from clinicians, patients, researchers, and industry stakeholders.

The review will evaluate whether the current system for prescribing, supplying, and researching medical cannabis is fit for purpose, and whether it has achieved the objectives envisioned when the 2018 rescheduling was enacted. Early findings flagged "significant variation in standards" across UK medical cannabis pharmacies � a concern that could drive tighter regulation of dispensing practices but also lay the groundwork for broader NHS integration.

This three-year programme represents the most significant regulatory opportunity since 2018 for expanding NHS access and potentially normalising CBPM prescribing within the public healthcare system.

What Conditions Drive the UK’s Patient Growth?

The UK’s private medical cannabis patient base is not uniform. Prescription data and clinic registries reveal a clear pattern in the conditions driving demand.

Primary Prescribing Indications

• Chronic pain â�� The single largest category, covering neuropathic pain, fibromyalgia, arthritis, and treatment-resistant pain syndromes
• Mental health conditions â�� Including PTSD, generalised anxiety disorder, OCD, depression, and ADHD
• Neurological conditions â�� Epilepsy, Parkinson’s disease, motor neurone disease, and Alzheimer’s
• Gastrointestinal conditions â�� Crohn’s disease and ulcerative colitis
• Cancer-related symptoms â�� Pain, appetite loss, and chemotherapy-induced nausea
• Sleep disorders â�� Insomnia and related conditions
• Palliative care â�� End-of-life symptom management

A 2025 patient survey by Releaf, gathering responses from 1,669 patients, found that 97% reported improved quality of life and 78% rated treatment as highly effective. Among women specifically, 95.4% reported effective treatment � a demographic that is increasingly driving patient growth.

The evidence picture is not without nuance. A major study published in The Lancet Psychiatry analysing 54 clinical trials over 45 years found no strong evidence that medicinal cannabis effectively treats anxiety, depression, or PTSD, while acknowledging potential benefits for epilepsy, chronic pain, and autism. This tension between real-world patient outcomes and randomised controlled trial evidence remains central to the NHS access debate.

Patient Costs: What UK Patients Actually Pay

For the estimated 80,000 patients accessing medical cannabis privately, cost is a significant factor � and one that is gradually decreasing as competition among clinics intensifies.

Typical Monthly Costs

Some clinics have aggressively reduced pricing to expand access. Membership models offering consultations for GBP 5 per month, pay-as-you-go appointments for GBP 29, and medication from GBP 20 per week have made medical cannabis accessible to a broader patient demographic. This price compression is a direct result of the competitive dynamics among 40+ private clinics � a market characteristic that distinguishes the UK from most other European medical cannabis frameworks.

The UK vs. Europe: How Access Models Compare

The UK’s private-clinic-driven model is unique in Europe. Understanding how it compares to other major markets â�� including Portugal, Germany, and the broader European landscape â�� provides context for both its strengths and its limitations.

Germany: The Public Healthcare Model

Germany is Europe’s largest medical cannabis market, valued at over EUR 670 million in 2025 with projections of EUR 1.32 billion by 2029. Following the April 2024 Cannabis Act (CanG), which removed cannabis from the German narcotics schedule, prescribing pathways were significantly simplified. German patients can access medical cannabis through the public health insurance system (Gesetzliche Krankenversicherung), and GPs are able to prescribe â�� a stark contrast to the UK’s specialist-only restriction. Patient numbers are estimated to exceed 100,000 active prescriptions in 2025.

Portugal: Export Powerhouse, Limited Domestic Access

Portugal occupies a distinctive position in the European cannabis landscape. The country decriminalised personal drug possession in 2001 � possession of up to 25 grams of cannabis herb or 5 grams of resin is treated as an administrative matter rather than a criminal offence. Medical cannabis has been legal since 2018, with patients able to obtain prescriptions for conditions including epilepsy, chronic pain, and chemotherapy side effects.

However, domestic patient access remains limited. An estimated 10,000 Portuguese patients relied on medicinal cannabis in 2025, constrained by high costs, a strict approval system, and the absence of public reimbursement. This creates a paradox: Portugal exported over 18 tonnes of medical cannabis in 2024 (a 54% year-on-year increase), making it one of Europe’s most important cultivation and supply hubs, yet its own citizens face significant barriers to accessing the products grown on Portuguese soil.

For travellers and those researching weed in Portugal, the legal landscape can be confusing. Despite decriminalisation, recreational cannabis remains illegal. There are no legal cannabis cafes in Portugal comparable to Amsterdam’s coffee shops â�� the cannabis cafe culture that once existed in Lisbon was curtailed in 2013. Portugal weed shops that do exist legally sell only CBD products. The distinction between decriminalisation and legalisation is critical: purchasing from unlicensed vendors in Lisbon or elsewhere carries risks including fines and, for foreigners, potential passport confiscation.

Portugal’s cannabis laws have evolved significantly since the landmark 2001 decriminalisation, but the country’s role in the European medical cannabis supply chain is now far more consequential than its domestic patient market. For UK patients and operators, Portugal’s importance is as a source of EU-GMP certified medical cannabis â�� accounting for approximately 10% of UK imports by volume in 2024, following Germany, Spain, and Poland as export destinations.

European Market Comparison

The broader European medical cannabis market was valued at USD 2.59 billion in 2024, with projections to reach USD 12.65 billion by 2033 â�� a CAGR of 18.33%. The UK and Germany together account for the vast majority of this value, and their continued growth trajectories will define Europe’s position in the global medical cannabis economy.

Regulatory Outlook: What Changes Are Coming?

The UK’s medical cannabis regulatory environment is in a period of active review, with several developments likely to shape the market through 2026 and beyond.

The ACMD Three-Year Programme (2025-2028)

The most consequential regulatory development is the ACMD review commissioned by the Home Office. This sweeping programme will evaluate:

• Whether the 2018 rescheduling has achieved its intended objectives
• The adequacy of prescribing, supplying, and researching frameworks
• Pharmacy standards (early findings flagged "significant variation")
• The potential for broadening NHS access pathways
• Research access to cannabis under Schedule 2

Industrial Hemp THC Threshold

In February 2025, the UK government raised the allowable THC content in industrial hemp from 0.2% to 0.3%, aligning with international standards. While this does not directly affect medical cannabis, it signals a government willing to make pragmatic regulatory adjustments.

MHRA and Product Approvals

The Medicines and Healthcare products Regulatory Agency (MHRA) continues to assess cannabis-based medicines through its standard licensing pathways. Currently, only three cannabis-derived medicines have marketing authorisation in the UK: Epidyolex (cannabidiol), Sativex (nabiximols), and Nabilone (a synthetic cannabinoid). The vast majority of CBPMs prescribed through private clinics are unlicensed specials � legal under Schedule 2 but without individual product marketing authorisation.

Rescheduling Debate

Cannabis itself remains a Schedule 1 substance under the Misuse of Drugs Regulations 2001, while prescribed CBPMs sit in Schedule 2. There are no legislative proposals before Parliament to reschedule cannabis further as of April 2026, though ministerial messaging from the Home Office and Department of Health and Social Care has focused on improving NHS access within the existing framework.

What the Market Expects

Industry observers anticipate that the ACMD review, combined with growing political pressure and the sheer weight of private-market prescription data, will produce incremental reforms rather than wholesale rescheduling. The most likely near-term changes include:

• Updated NICE guidelines reflecting real-world evidence
• Expanded training programmes for NHS clinicians
• Clarified pharmacy standards and dispensing regulations
• Possible electronic prescribing integration for CBPMs
• Enhanced quality assurance requirements for unlicensed specials

Investment Landscape: Where Capital Is Flowing

For investors evaluating the UK medical cannabis market, the data points toward a sector transitioning from early-stage growth to a more structured, if still concentrated, industry.

Market trajectory: From $298 million in 2025 to an estimated GBP 539 million by 2029 � a 104% year-on-year growth rate that outpaces most European healthcare sectors.

Vertical integration: Curaleaf International’s acquisition of Sapphire Medical Clinics exemplifies the trend toward vertically integrated models â�� from import and processing to prescribing and dispensing within a single corporate structure.

Supply chain investment: IPS Pharma’s GBP 7 million organic cannabis supply deal with Puro (New Zealand) and Curaleaf’s strategic partnership with Dalgety signal continued capital flowing into supply chain diversification.

Regulatory catalysts: The ACMD review and potential NHS access reforms represent regulatory catalysts that could significantly expand the addressable market. A shift from 80,000 to even 190,000 patients by 2029 would require proportional growth in supply, dispensing, and clinical infrastructure.

Risk factors: Prescriber concentration (10 doctors writing 52% of prescriptions), supply chain concentration (two importers controlling 70%+ of volume), and regulatory uncertainty around pharmacy standards and product quality all represent structural risks that investors must weigh.

How GrowerIQ Supports Medical Cannabis Compliance in Growing European Markets

As the UK market scales from 80,000 toward 190,000 patients, and as European medical cannabis markets collectively approach USD 13 billion, the compliance and quality assurance infrastructure underpinning this growth becomes increasingly critical. Producers, importers, and dispensers operating across jurisdictions face a matrix of regulatory requirements � EU-GMP certification, batch traceability, import documentation, and pharmacovigilance obligations that vary by country.

EU-GMP Compliance and Batch Traceability

GrowerIQ is the only cannabis seed-to-sale platform that includes a fully integrated Quality Management System (QMS), independently validated by RQC to meet EU-GMP and PIC/S standards. For producers supplying the UK market from Portugal, Spain, Canada, or Australia, this means every batch is tracked from cultivation through processing, packaging, and export � with digital sign-offs ensuring SOPs are followed at each production stage.

Deviation Tracking and CAPAs

The ACMD review’s finding of "significant variation in standards" across UK medical cannabis pharmacies underscores the need for robust deviation tracking. GrowerIQ’s integrated Deviation Reports and Corrective Action Plans (CAPAs) are connected directly to batch data, enabling producers to identify, document, and resolve quality issues before they reach patients â�� a requirement that will likely tighten as UK pharmacy standards are formalised.

Supply Chain Documentation for Import Markets

UK medical cannabis importers must satisfy Home Office licensing requirements, MHRA standards, and country-of-origin export documentation. GrowerIQ’s platform generates the batch-level traceability data that importers and regulators require â�� from cultivation environment records and lab results to chain-of-custody documentation spanning international borders.

Prescription and Distribution Compliance

As medical cannabis markets mature, the regulatory expectation is moving toward pharmaceutical-grade oversight. GrowerIQ supports licensed operators in maintaining the compliance infrastructure needed to operate in markets like the UK, Germany, and Portugal � where quality assurance is not optional but a regulatory condition of market access.

For operators looking to enter or expand within the UK’s rapidly growing medical cannabis sector, the combination of GMP-validated production tracking, integrated quality management, and regulatory reporting capabilities positions GrowerIQ as the compliance backbone for Europe’s evolving medical cannabis supply chain.

This analysis is current as of April 2026 and draws on data from Home Office import records, NHSBSA Freedom of Information releases, Prohibition Partners market reports, the ACMD call for evidence, and clinic-level prescription data. For the latest regulatory developments, refer to GOV.UK Cannabis-Based Products for Medicinal Use and the ACMD 2025-2028 work programme.

Sources:

• Data Shows 262% Rise in Prescription UK Volumes Since 2022 â�� Business of Cannabis
• What Was 2025 Like for the UK’s Medical Cannabis Sector â�� The Canary
• Medical Cannabis Prescriptions â�� The Facts Behind the Headlines â�� MCCS
• Medical Cannabis in the UK: Patient Numbers and Impact in 2025 â�� Releaf
• UK Medical Cannabis White Paper 2025 â�� Prohibition Partners
• Thousands of UK Patients Left Suffering â�� Cannabis Health News
• Ten Private Doctors Prescribe Over Half UK Medical Cannabis â�� British Brief
• Cannabis Rescheduling in the UK: What It Means for Business in 2026 â�� Cannabis Europa
• ACMD 3-Year Work Programme 2025-2028 â�� GOV.UK
• UK Medical Cannabis: How the Winner-Takes-All Market Works â�� Business of Cannabis
• New Report: UK and Germany Medical Cannabis Markets Both Double in 2025 â�� Business of Cannabis
• Europe’s Medical Cannabis Market Surges Toward $13 Billion â�� Cannabis & Tech Today
• Four UK Medical Cannabis Business Trends to Watch in 2026 â�� London Business Magazine
• Cannabis Laws in Portugal 2025/2026 â�� CannaTrailz
• Why Portugal Could Be Europe’s Medical Cannabis Capital â�� The Portugal News
• Significant Variation in Standards Found Across UK Medical Cannabis Pharmacies â�� Cannabis Health News
• European Medical Cannabis Market Size and Forecast 2025-2033 â�� IMARC Group
• IPS Pharma Signs GBP 7M+ Landmark Import Agreement "},"caller":{"type":"direct"}}],"stop_reason":"tool_use